SOTIO® SO-L103 is a first-in-class small molecule program addressing a novel target in tumor metabolism. It is developed in collaboration with Lead Discovery Center and Max Planck Innovation. Under the terms of the agreement, LDC and its academic partners perform further lead optimization activities and identify corresponding biomarkers for the program in close collaboration with SOTIO. Upon the selection of the pre-clinical candidate, SOTIO will be responsible for the preclinical and clinical development as well as the subsequent marketing and commercialization.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies